Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR.

Verbrugge SE, Al M, Assaraf YG, Kammerer S, Chandrupatla DM, Honeywell R, Musters RP, Giovannetti E, O'Toole T, Scheffer GL, Krige D, de Gruijl TD, Niessen HW, Lems WF, Kramer PA, Scheper RJ, Cloos J, Ossenkoppele GJ, Peters GJ, Jansen G.

Oncotarget. 2016 Feb 2;7(5):5240-57. doi: 10.18632/oncotarget.6169.

2.

The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway.

Smith EM, Zhang L, Walker BA, Davenport EL, Aronson LI, Krige D, Hooftman L, Drummond AH, Morgan GJ, Davies FE.

Oncotarget. 2015 Jul 10;6(19):17314-27.

3.

The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria.

Skinner-Adams TS, Peatey CL, Anderson K, Trenholme KR, Krige D, Brown CL, Stack C, Nsangou DM, Mathews RT, Thivierge K, Dalton JP, Gardiner DL.

Antimicrob Agents Chemother. 2012 Jun;56(6):3244-9. doi: 10.1128/AAC.06245-11. Epub 2012 Mar 26.

4.

Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin.

Huertas D, Soler M, Moreto J, Villanueva A, Martinez A, Vidal A, Charlton M, Moffat D, Patel S, McDermott J, Owen J, Brotherton D, Krige D, Cuthill S, Esteller M.

Oncogene. 2012 Mar 15;31(11):1408-18. doi: 10.1038/onc.2011.335. Epub 2011 Aug 1.

5.

Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs.

Needham LA, Davidson AH, Bawden LJ, Belfield A, Bone EA, Brotherton DH, Bryant S, Charlton MH, Clark VL, Davies SJ, Donald A, Day FA, Krige D, Legris V, McDermott J, McGovern Y, Owen J, Patel SR, Pintat S, Testar RJ, Wells GM, Moffat D, Drummond AH.

J Pharmacol Exp Ther. 2011 Oct;339(1):132-42. doi: 10.1124/jpet.111.183640. Epub 2011 Jul 21.

PMID:
21778281
6.

Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia.

Jenkins C, Hewamana S, Krige D, Pepper C, Burnett A.

Leuk Res. 2011 May;35(5):677-81. doi: 10.1016/j.leukres.2010.10.030. Epub 2010 Dec 9.

PMID:
21145592
7.

Aminopeptidase inhibition as a targeted treatment strategy in myeloma.

Moore HE, Davenport EL, Smith EM, Muralikrishnan S, Dunlop AS, Walker BA, Krige D, Drummond AH, Hooftman L, Morgan GJ, Davies FE.

Mol Cancer Ther. 2009 Apr;8(4):762-70. doi: 10.1158/1535-7163.MCT-08-0735.

8.

CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells.

Krige D, Needham LA, Bawden LJ, Flores N, Farmer H, Miles LE, Stone E, Callaghan J, Chandler S, Clark VL, Kirwin-Jones P, Legris V, Owen J, Patel T, Wood S, Box G, Laber D, Odedra R, Wright A, Wood LM, Eccles SA, Bone EA, Ayscough A, Drummond AH.

Cancer Res. 2008 Aug 15;68(16):6669-79. doi: 10.1158/0008-5472.CAN-07-6627.

9.

Identification of potential stroke targets by lentiviral vector mediated overexpression of HIF-1 alpha and HIF-2 alpha in a primary neuronal model of hypoxia.

Ralph GS, Parham S, Lee SR, Beard GL, Craigon MH, Ward N, White JR, Barber RD, Rayner W, Kingsman SM, Mundy CR, Mazarakis ND, Krige D.

J Cereb Blood Flow Metab. 2004 Feb;24(2):245-58.

PMID:
14747751
10.

Sequence variation in the early genes E1E4, E6 and E7 of human papilloma virus type 6.

Krige D, Mills HR, Berrie EL, Doherty NC, Jones DK, Ryan CA, Davies H, Myint S, McCance DJ, Layton GT, French TJ.

Virus Res. 1997 Jun;49(2):187-91.

PMID:
9213393
11.

A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease.

Taylor DJ, Krige D, Barnes PR, Kemp GJ, Carroll MT, Mann VM, Cooper JM, Marsden CD, Schapira AH.

J Neurol Sci. 1994 Aug;125(1):77-81.

PMID:
7964892
12.

Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group.

Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AH.

Ann Neurol. 1992 Dec;32(6):782-8.

PMID:
1471869
13.

Human mitochondrial complex I dysfunction.

Cooper JM, Mann VM, Krige D, Schapira AH.

Biochim Biophys Acta. 1992 Jul 17;1101(2):198-203. Review.

PMID:
1633185
14.

Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease.

Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD.

Brain. 1992 Apr;115 ( Pt 2):333-42.

PMID:
1606472
15.

Mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson's Disease Research Group.

Schapira AH, Mann VM, Cooper JM, Krige D, Jenner PJ, Marsden CD.

Ann Neurol. 1992;32 Suppl:S116-24. Review.

PMID:
1510369
16.

The use of a geographical information system for hospital catchment area research in Natal/KwaZulu.

Zwarenstein M, Krige D, Wolff B.

S Afr Med J. 1991 Nov 16;80(10):497-500.

PMID:
1948466

Supplemental Content

Support Center